Current
2.4×
5-Year Average
2.8×
All-Time High
7.3×
All-Time Low
1.7×
P/S Ratio daily chart for Pfizer (PFE)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/S Ratio for Pfizer (PFE) from 2001 to 2025
| 2025 | $141.50B | $62.58B | 2.3× | -0.1× | |
| 2024 | $150.35B | $63.63B | 2.4× | -0.4× | |
| 2023 | $162.58B | $59.55B | 2.7× | -0.1× | |
| 2022 | $287.71B | $100.33B | 2.9× | -1.2× | |
| 2021 | $331.62B | $81.29B | 4.1× | -0.8× | |
| 2020 | $204.74B | $41.86B | 4.9× | +0.9× | |
| 2019 | $205.57B | $51.75B | 4.0× | -0.5× | |
| 2018 | $239.51B | $53.65B | 4.5× | +0.6× | |
| 2017 | $204.71B | $52.55B | 3.9× | +0.4× | |
| 2016 | $186.90B | $52.82B | 3.5× | -0.3× | |
| 2015 | $188.92B | $48.85B | 3.9× | +0.1× | |
| 2014 | $185.92B | $49.60B | 3.7× | +0.2× | |
| 2013 | $187.10B | $52.67B | 3.6× | +0.6× | |
| 2012 | $173.97B | $59.51B | 2.9× | +0.6× | |
| 2011 | $156.59B | $67.42B | 2.3× | +0.4× | |
| 2010 | $132.95B | $67.81B | 2.0× | -0.4× | |
| 2009 | $116.58B | $50.01B | 2.3× | -0.0× | |
| 2008 | $112.80B | $48.30B | 2.3× | -0.7× | |
| 2007 | $146.02B | $48.42B | 3.0× | -0.5× | |
| 2006 | $175.36B | $49.28B | 3.6× | +0.4× | |
| 2005 | $162.02B | $51.30B | 3.2× | -0.5× | |
| 2004 | $190.21B | $52.52B | 3.6× | -2.0× | |
| 2003 | $254.07B | $45.19B | 5.6× | +0.2× | |
| 2002 | $176.98B | $32.37B | 5.5× | -1.8× | |
| 2001 | $234.90B | $32.26B | 7.3× | — |
- 20252.3×
- 20242.4×
- 20232.7×
- 20222.9×
- 20214.1×
- 20204.9×
- 20194.0×
- 20184.5×
- 20173.9×
- 20163.5×
- 20153.9×
- 20143.7×
- 20133.6×
- 20122.9×
- 20112.3×
- 20102.0×
- 20092.3×
- 20082.3×
- 20073.0×
- 20063.6×
- 20053.2×
- 20043.6×
- 20035.6×
- 20025.5×
- 20017.3×
About P/S Ratio at Pfizer (PFE)
Pfizer (PFE) P/S ratio is 2.4× as of June 5, 2026. The 5-year average is 2.8×. The sector median currently stands at 3.5×. The current ratio is at the 31th percentile of its own 10-year history.
Pfizer (PFE) historical P/S ratio has ranged from a low of 1.7× (2010) to a high of 7.3× (2001) in the available daily series.
The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.
Pfizer P/S Ratio by Year
Pfizer P/S Ratio 2025: 2.3×
Pfizer (PFE) P/S ratio in 2025 was 2.3×, contracted from 2.4× the prior year.
Pfizer P/S Ratio 2024: 2.4×
Pfizer (PFE) P/S ratio in 2024 was 2.4×, contracted from 2.7× the prior year.
Pfizer P/S Ratio 2023: 2.7×
Pfizer (PFE) P/S ratio in 2023 was 2.7×, contracted from 2.9× the prior year.
Pfizer P/S Ratio 2022: 2.9×
Pfizer (PFE) P/S ratio in 2022 was 2.9×, contracted from 4.1× the prior year.
Pfizer P/S Ratio 2021: 4.1×
Pfizer (PFE) P/S ratio in 2021 was 4.1×.
Sector peers by P/S Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/S Ratio — table
Healthcare peers of Pfizer (PFE), ranked by P/S ratio.
| 2.1× | |
| 2.1× | |
| 2.1× | |
| 1.9× | |
| 1.9× | |
| 1.7× | |
| 1.6× | |
| 1.6× | |
| 1.4× | |
| 1.4× | |
| 1.1× | |
| 0.8× | |
| 0.7× | |
| 0.6× | |
| 0.6× | |
| 0.5× | |
| 0.3× | |
| 0.3× | |
| 0.3× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.1× |
- 2.1×
- 1.7×
- 1.4×
- 1.1×
- 0.7×
- 0.3×
- 0.3×
- 0.2×
- 0.2×
- 0.2×
- 0.1×
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric